"Sarcoma, Synovial" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant neoplasm arising from tenosynovial tissue of the joints and in synovial cells of tendons and bursae. The legs are the most common site, but the tumor can occur in the abdominal wall and other trunk muscles. There are two recognized types: the monophasic (characterized by sheaths of monotonous spindle cells) and the biphasic (characterized by slit-like spaces or clefts within the tumor, lined by cuboidal or tall columnar epithelial cells). These sarcomas occur most commonly in the second and fourth decades of life. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1363)
| Descriptor ID |
D013584
|
| MeSH Number(s) |
C04.557.450.565.835 C04.557.450.795.875
|
| Concept/Terms |
Sarcoma, Synovial- Sarcoma, Synovial
- Sarcomas, Synovial
- Synovial Sarcoma
- Synovial Sarcomas
- Synovioma
- Synoviomas
|
Below are MeSH descriptors whose meaning is more general than "Sarcoma, Synovial".
Below are MeSH descriptors whose meaning is more specific than "Sarcoma, Synovial".
This graph shows the total number of publications written about "Sarcoma, Synovial" by people in this website by year, and whether "Sarcoma, Synovial" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 2 | 1 | 3 |
| 2004 | 1 | 0 | 1 |
| 2005 | 3 | 0 | 3 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2013 | 1 | 1 | 2 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2018 | 2 | 0 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sarcoma, Synovial" by people in Profiles.
-
FZD10-targeted a-radioimmunotherapy with 225 Ac-labeled OTSA101 achieves complete remission in a synovial sarcoma model. Cancer Sci. 2022 Feb; 113(2):721-732.
-
Soft-Tissue Tumors of the Hand-Imaging Features. Can Assoc Radiol J. 2020 May; 71(2):161-173.
-
a-particle therapy for synovial sarcoma in the mouse using an astatine-211-labeled antibody against frizzled homolog 10. Cancer Sci. 2018 Jul; 109(7):2302-2309.
-
A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients. BMC Cancer. 2018 Jun 08; 18(1):646.
-
Epigenetic regulation of SMARCB1 By miR-206, -381 and -671-5p is evident in a variety of SMARCB1 immunonegative soft tissue sarcomas, while miR-765 appears specific for epithelioid sarcoma. A miRNA study of 223 soft tissue sarcomas. Genes Chromosomes Cancer. 2016 10; 55(10):786-802.
-
The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies. Cancer Res. 2015 Sep 15; 75(18):3865-3878.
-
Assessment of multimodality therapy use for extremity sarcoma in the United States. J Surg Oncol. 2014 Apr; 109(5):395-404.
-
Exomic analysis of myxoid liposarcomas, synovial sarcomas, and osteosarcomas. Genes Chromosomes Cancer. 2014 Jan; 53(1):15-24.
-
Radioimmunotherapy of human synovial sarcoma using a monoclonal antibody against FZD10. Cancer Sci. 2008 Feb; 99(2):432-40.
-
Immunostaining for SYT protein discriminates synovial sarcoma from other soft tissue tumors: analysis of 146 cases. Mod Pathol. 2007 May; 20(5):522-8.